Keywords: commerzbank, adopts, new, rating, drug, stocks, views
Commerzbank adopts new rating for drug stocks; views AstraZeneca, Aventis
Article | 14 December 1999
Commerzbank Global Equities says it is adopting a new five-tierrecommendation structure, as follows: buy (15%+ outperformance expected within a year); accumulate (5% ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
